Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis

BackgroundIntestinal dysbiosis was considered a pivotal pathological mechanism underlying sarcopenia. Despite the fervor surrounding research in this domain, substantial controversy persists regarding the obtained outcomes.ObjectiveTo systematically summarized the disparities in gut microbiota compo...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangning Wang, Yujie Li, Huisong Liu, Xinjuan Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2025.1513253/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591711883231232
author Guangning Wang
Yujie Li
Huisong Liu
Xinjuan Yu
author_facet Guangning Wang
Yujie Li
Huisong Liu
Xinjuan Yu
author_sort Guangning Wang
collection DOAJ
description BackgroundIntestinal dysbiosis was considered a pivotal pathological mechanism underlying sarcopenia. Despite the fervor surrounding research in this domain, substantial controversy persists regarding the obtained outcomes.ObjectiveTo systematically summarized the disparities in gut microbiota composition between the group afflicted by sarcopenia and non-sarcopenia controls.MethodsPubMed, Medline, CINAHL, EMBASE, Scopus, Web of Science and Google Scholer, Cochrane Library and gray literature sources were systematically searched for in randomized controlled trials. Meta-analysis and random-effects meta-regression were conducted using Rev. Man 5.3. Overall effect was measured using Hedges’s g and determined using Z-statistics. Cochran’s Q test and I2 were used to investigate heterogeneity. The Newcastle-Ottawa Scale was used to assess overall quality of evidence.ResultsTen studies, including 421 cases of sarcopenia and 1,642 cases of controls, were included in the meta-analysis. Patients with sarcopenia showed significantly reduced gut microbiota in α diversity, and β diversity was significantly different in 8/9 of included studies. We also found more abundance of phylum Proteobacteria and genus Escherichia-Shigella, and less abundance of phylum Firmicutes and genus Faecalibacterium, Prevotella 9, Blautia in the sarcopenia group.ConclusionThe gut microbiota composition in patients with sarcopenia has undergone alterations, serving as a fundamental reference for further investigation into the potential pathogenic mechanisms and treatment strategies for sarcopenia.
format Article
id doaj-art-837d5109b4c74c26ae2b8dc7ab4d72e7
institution Kabale University
issn 1664-302X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj-art-837d5109b4c74c26ae2b8dc7ab4d72e72025-01-22T07:11:09ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2025-01-011610.3389/fmicb.2025.15132531513253Gut microbiota in patients with sarcopenia: a systematic review and meta-analysisGuangning Wang0Yujie Li1Huisong Liu2Xinjuan Yu3Department of Critical Care Medicine, Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaReproductive Medicine Center, Women and Children’s Hospital, Qingdao University, Qingdao, ChinaDepartment of Nursing, Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Clinical Research Center, Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaBackgroundIntestinal dysbiosis was considered a pivotal pathological mechanism underlying sarcopenia. Despite the fervor surrounding research in this domain, substantial controversy persists regarding the obtained outcomes.ObjectiveTo systematically summarized the disparities in gut microbiota composition between the group afflicted by sarcopenia and non-sarcopenia controls.MethodsPubMed, Medline, CINAHL, EMBASE, Scopus, Web of Science and Google Scholer, Cochrane Library and gray literature sources were systematically searched for in randomized controlled trials. Meta-analysis and random-effects meta-regression were conducted using Rev. Man 5.3. Overall effect was measured using Hedges’s g and determined using Z-statistics. Cochran’s Q test and I2 were used to investigate heterogeneity. The Newcastle-Ottawa Scale was used to assess overall quality of evidence.ResultsTen studies, including 421 cases of sarcopenia and 1,642 cases of controls, were included in the meta-analysis. Patients with sarcopenia showed significantly reduced gut microbiota in α diversity, and β diversity was significantly different in 8/9 of included studies. We also found more abundance of phylum Proteobacteria and genus Escherichia-Shigella, and less abundance of phylum Firmicutes and genus Faecalibacterium, Prevotella 9, Blautia in the sarcopenia group.ConclusionThe gut microbiota composition in patients with sarcopenia has undergone alterations, serving as a fundamental reference for further investigation into the potential pathogenic mechanisms and treatment strategies for sarcopenia.https://www.frontiersin.org/articles/10.3389/fmicb.2025.1513253/fullgut microbiotasarcopeniamusculoskeletal diseaseseffectsmeta-analysis
spellingShingle Guangning Wang
Yujie Li
Huisong Liu
Xinjuan Yu
Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
Frontiers in Microbiology
gut microbiota
sarcopenia
musculoskeletal diseases
effects
meta-analysis
title Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
title_full Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
title_fullStr Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
title_full_unstemmed Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
title_short Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis
title_sort gut microbiota in patients with sarcopenia a systematic review and meta analysis
topic gut microbiota
sarcopenia
musculoskeletal diseases
effects
meta-analysis
url https://www.frontiersin.org/articles/10.3389/fmicb.2025.1513253/full
work_keys_str_mv AT guangningwang gutmicrobiotainpatientswithsarcopeniaasystematicreviewandmetaanalysis
AT yujieli gutmicrobiotainpatientswithsarcopeniaasystematicreviewandmetaanalysis
AT huisongliu gutmicrobiotainpatientswithsarcopeniaasystematicreviewandmetaanalysis
AT xinjuanyu gutmicrobiotainpatientswithsarcopeniaasystematicreviewandmetaanalysis